Heptares eyes promise of the East as it seeks out new partnerships
This article was originally published in Scrip
Heptares Therapeutics has already established a solid link with Japan through its G-protein coupled receptor (GPCR) drug discovery collaboration with Takeda signed nearly a year ago, which seems to have piqued the attention of other potential partners in the country.
You may also be interested in...
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.
Corporate consolidation and specialization were major threads running through the 2010s in Japan. Reimbursement pricing issues continued to dominate the policy sphere while new forms of therapy benefited from positive regulatory reforms.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.